Brian Orelli, PhD

Will slow but steady win the race?

Unless the country can slow the pace of COVID-19's spread, the number of people with cases severe enough that they require ventilators to breathe could totally outstrip our supply of the machines.

The pharma giant is helping any way it can.

But now, the agency isn't so sure about whether people can transmit the disease to dogs and cats.

The test can produce results in under four hours.

The healthcare companies couldn't sidestep the COVID-19 slump.

The company hopes to have 1 million doses of its vaccine ready by the end of the year.

The company added its name to the long list of companies helping develop a vaccine to the coronavirus that causes COVID-19.

The drug combination has to be injected, but only having to deal with treatment once a month could be worth it for many patients.

Two patients treated with one of the biotech's drugs had partial responses.

The head of the World Health Organization describes the threat of the coronavirus outbreak reaching pandemic proportions as "very real."

Even healthcare companies can't escape the overall market downturn.

Cedars-Sinai researchers say the window to prevent a major epidemic is closing.

Investors can't figure out how to value this high-growth company.

Not yet, but multiple drugmakers are working on treatments and vaccines.

The company has set terms for its initial public offering.

The FDA is reviewing the biotech's marketing application for its hereditary angioedema treatment berotralstat.

The acquisition moves the Invisalign-focused company further into digital dentistry.

Sales of Dextenza are picking up steam, and new data is around the corner.

The companies will complement its precision oncology products.